Henry Ofori

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 1

Top Topics

Early Breast Cancer

Combination Therapy

Top Venues

The Annals of pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Farah Raheem, Henry Ofori, Lacey Simpson, Vishal S Shah
Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer. The Annals of pharmacotherapy (2022)